BRIEF-Oncolytics says ovarian cancer drug shows benefit in mid-stage study

Mon Mar 21, 2016 5:10pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

March 21 (Reuters) - Oncolytics Biotech

* Update for randomized phase ii clinical trial reolysin in combination with paclitaxel in patients with ovarian cancer

* Performed an intent-to-treat analysis of tumour response, which showed statistically significantly higher full response rates Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)